Learn more about how Foundation Medicine can partner with care teams through Epic integration. Heading to Epic UGM 2025? Our team would love the chance to meet with you there:

This pan-tumor HRD biomarker predicted benefit from rucaparib better than a homologous recombination repair (HRR) alteration alone. Check out the paper to learn more about this functional HRD readout:

#ICYMI data from the pan-tumor PARP inhibitor trial LODESTAR was reanalyzed using Foundation Medicine’s homologous recombination deficiency signature (HRDsig).

@ALKPositiveinc More insights on the advancements in lung cancer diagnostics and treatments here:

This #WorldLungCancerDay, we are proud to support patients like Greg and organizations like @ALKPositiveinc on spreading greater awareness of the disease and promoting further research, education and resources for those affected.

New Publication❗- “LODESTAR: A single-arm phase II study of rucaparib in solid tumors with pathogenic germline or somatic variants in homologous recombination repair genes.” Read the research here:

When Summer was diagnosed with stage IV lung cancer, #biomarker #testing provided answers and options that equipped her and her medical team with a treatment plan. More resources and information on Foundation Medicine and biomarker testing:

Visit our Precision Points blog to explore the latest on recent advances in precision medicine and the resources available to ensure patients can access high-quality tests that can help inform their treatment. 🔬 Click here to explore:

#NewResearch in @OncJournal: “Clinical utility of companion diagnostic biomarker results below the limit of detection in comprehensive genomic profiling of patients with advanced non-small cell lung cancer.” Click here for the full publication:

July is UV Awareness Month, a time dedicated to share resources and education around the dangers of ultraviolet (UV) radiation. UV exposure involves risks, including sunburns and skin cancer. Read our post for some key facts.

#NewResearch in @Nature_NPJ precision oncology: “Tissue-based genomic profiling of 300,000 tumors highlights the detection of variants with low allele fraction.” Explore the publication here:

We’re still thinking back about our time at #ASCO25! The meeting always provides some time to reflect upon and learn more about the latest advancements in oncology. We asked some of our team members what gives them hope about the future of cancer care. Hear what they had to say.

Utilizing Foundation Medicine’s tissue-free treatment response monitoring assay, new #research demonstrated the clinical value of treatment response monitoring by ctDNA in real-world patients with non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).

This year, Foundation Medicine celebrates our 15th anniversary. Look back at the milestones we’ve achieved in a new blog from our CEO Dan Malarek:

Honored to have joined the oncology community and to have been part of #ASCO25. Our team had so many great interactions and conversations last week in Chicago. #WeAreFMI #MissNotOne

Stop by our booth F.02 or schedule a meeting with our experts to learn how we can help move your heme program forward: #EHA2025.

Foundation Medicine is thrilled to be attending #EHA2025 in Milan, Italy, June 12-15. Excited to share what’s ahead in hematology diagnostics & how our latest advancements can support your research and drug development programs.

Explore and learn more at the link here:

We’re honored to be a part of all the innovative research being presented at #ASCO25, including an oral presentation in #ProstateCancer & our tissue-free response monitoring. Hear from Dr. Lincoln Pasquina, Director, Clinical Development at Foundation Medicine on our research.

New research being presented at #ASCO25 showcases new innovations in #BreastCancer treatment and care. Hear some quick highlights from Dr. Julia Quintanilha, Senior Scientist at Foundation Medicine. Learn more: